Ensign Peak Advisors
TVTX icon

Ensign Peak Advisors’s Travere Therapeutics TVTX Stock Holding History

Ensign Peak Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.6M Sell
591,815
-123,892
-17% -$5.49M 0.06% 242
2026
Q1 		$21.3M Sell
715,707
-89,508
-11% -$2.68M 0.04% 297
2025
Q4 		$30.8M Sell
805,215
-46,987
-6% -$1.53M 0.05% 240
2025
Q3 		$20.4M Sell
852,202
-6,632
-0.8% -$125K 0.03% 308
2025
Q2 		$12.7M Buy
858,834
+360,100
+72% +$5.97M 0.02% 416
2025
Q1 		$8.94M Buy
+498,734
New +$10.1M 0.02% 493
2023
Q3 		– Sell
-110,088
Closed -$1.69M – 1765
2023
Q2 		$1.69M Hold
110,088
– – ﹤0.01% 941
2023
Q1 		$2.48M Buy
110,088
+32,858
+43% +$698K 0.01% 755
2022
Q4 		$1.62M Sell
77,230
-20,100
-21% -$426K ﹤0.01% 893
2022
Q3 		$2.4M Buy
97,330
+20,431
+27% +$528K 0.01% 720
2022
Q2 		$1.86M Buy
76,899
+65,819
+594% +$1.66M ﹤0.01% 829
2022
Q1 		$286K Buy
+11,080
New +$294K ﹤0.01% 1770

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ensign Peak Advisors's TVTX Position: Q2 2026 in Review

Ensign Peak Advisors reduced its Travere Therapeutics (TVTX) stake by 17% in Q2 2026, selling an estimated $5.49M and leaving 591,815 shares worth $33.6M. The position accounts for 0.06% of the portfolio, ranked #242.

Ensign Peak Advisors first reported a position in TVTX in Q1 2022 and has held it in 12 quarters since. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Ensign Peak Advisors held 591,815 shares of Travere Therapeutics worth $33.6M as of Q2 2026.
  • Ensign Peak Advisors sold 123,892 Travere Therapeutics shares in Q2 2026, an estimated $5.49M.
  • Travere Therapeutics made up 0.06% of Ensign Peak Advisors's portfolio in Q2 2026, its #242 holding.
  • Ensign Peak Advisors first reported a position in Travere Therapeutics in Q1 2022 and has held it in 12 quarters since.
  • 321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.